Edward A. Stadtmauer

Dr. Edward A. Stadtmauer is a Professor and Director of Hematologic Malignancies Clinical/Translational Research in the Division of Hematology/Oncology at the Perelman School of Medicine, University of Pennsylvania. He holds the prestigious Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor position and practices at the Abramson Cancer Center within the Perelman Center for Advanced Medicine. Dr. Stadtmauer has hospital privileges at the Hospital of the University of Pennsylvania and sees patients age 18 and up with hematologic malignancies.

Dr. Stadtmauer's educational background includes:

• Medical Degree: University of Pennsylvania School of Medicine
• Residency: Bronx Municipal Hospital - Albert Einstein College
• Fellowship: Hospital of the University of Pennsylvania

Dr. Stadtmauer's research focuses on hematologic malignancies, with particular expertise in multiple myeloma and acute myeloid leukemia (AML). His work spans both clinical and translational domains, investigating novel therapeutic approaches including CAR T-cell therapy, bispecific antibodies like teclistamab, and mechanisms of treatment resistance. A significant portion of his research involves clinical trial analysis, particularly from the BMT CTN 0702 (STaMINA) trial for multiple myeloma. His laboratory research explores disease mechanisms, such as the role of IL-6 in myeloma progression and cytokine-mediated resistance to CAR T therapy in AML.

Dr. Stadtmauer holds the distinguished Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor position at the University of Pennsylvania, reflecting his significant contributions to the field of hematology/oncology.

As Director of Hematologic Malignancies Clinical/Translational Research, Dr. Stadtmauer leads a robust research program with active involvement in multiple clinical trials and translational studies. His recent publication record demonstrates consistent funding support for his work in hematologic malignancies. While specific grant details aren't provided in the available text, his leadership position and extensive collaborative research suggest substantial research funding from both institutional and external sources. Patient reviews consistently rate him highly (5.0 average from 1,297 reviews), with comments highlighting his knowledge, thoroughness, listening skills, and compassionate care for patients and their families.

Dr. Stadtmauer directs the Hematologic Malignancies Clinical/Translational Research program, which focuses on bridging laboratory discoveries with clinical applications for patients with blood cancers. His research team collaborates extensively with other investigators at Penn Medicine and across institutions, as evidenced by his numerous multi-author publications in high-impact journals. His clinical practice at the Abramson Cancer Center allows him to directly apply research findings to patient care while identifying new research questions from clinical observations.